Scailyte AG Announces a partnership with Sirona DX

Scailyte, a single-cell biomarker discovery company and Sirona Dx, a leader in multiomic single-cell analytical services, announce a strategic partnership to accelerate the development of Advanced Therapies. The companies will create a powerful biomarker discovery engine, leveraging Sirona Dx technical and laboratory workflow solutions in combination with  Scailyte’s AI-driven data analytics platform ScaiVision™ to serve Biopharma and Biotech. The joint platform will enable discovery and validation of ultra-sensitive biomarkers thanks to Sirona Dx leading technical capabilities in single-cell analysis, and the ability of ScaiVision™ to detect complex molecular signatures in biological samples.

The combined workflow will focus on applications within oncology and immunology, including qualification and stratification of patients for clinical trials, analysis of clinical trial results on a deep cellular level or and to advance efficacy and manufacturing processes during CGT development.

The first wave of projects with pharmaceutical and diagnostic companies, will begin in Q2-2022.